News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alpharma Inc. (ALO) Closes Transaction to License U.S. Rights for Prescription Topical NSAID Pain Drug



10/12/2007 11:17:21 AM

BRIDGEWATER, NJ--(Marketwire - October 12, 2007) - Alpharma Inc. (NYSE: ALO) today announced its affiliate, Alpharma Ireland Limited, has closed its previously announced agreement with IDEA AG ("IDEA"), a privately held biopharmaceutical company with headquarters in Munich, Germany, to license the exclusive United States rights to ketoprofen in Transfersome® gel, a prescription topical NSAID (non-steroidal anti-inflammatory drug) in Phase III clinical development. This license includes access to IDEA's innovative Transfersome® technology platform that delivers drugs locally to targeted areas.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES